Neal D. Shore, MD
Carolina Urologic Research Center, Myrtle Beach, SCAuthored Items
January 19, 2022 | Video Library
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer.
Michael S. Cookson, MD, MMHC, Neal D. Shore, MD, Daniel J. George, MD, Hideyuki Akaza, MD, Daniel R. Saltzstein, MD, Ronald Tutrone, MD, Alberto Bossi, MD, Bruce Brown, MD, Bryan Selby, MS, Sophia Lu, PhD, Jackie Walling, MBChB, PhD, Bertrand Tombal, MD, PhD, Fred Saad, MD
December 16, 2021 | December 2021 Vol 12, No 12
November 23, 2021 | Video Library
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent.
November 8, 2021 | Video Library
Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging.
November 1, 2021 | Video Library
Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment.
October 20, 2021 | Video Library
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY® (piflufolastat F 18).
Last modified: December 17, 2021